The Pressure To Move Fast
Every team building a new cell therapy hits the same wall. Investors want speed. Patients need speed. But biology does not care about either. I have run programs where the fastest path on paper turned into the slowest path in practice, and I have seen the reverse too. After years of moving between academic labs and startups, I have a rough rule for telling the difference between a shortcut that saves time and one that just moves the delay downstream.
The Shortcut That Works: Borrowing A Validated Platform
When I start a new therapeutic idea, I look hard at whether an existing, well-characterized platform can carry it. This is not about cutting corners on safety. It is about not re-solving a problem someone has already solved well.
If a cell engineering method or delivery system has already been through rigorous characterization elsewhere, reusing it is not laziness. It is discipline. You are choosing to spend your novelty budget on the one thing that is actually new about your program, instead of spreading it across ten small inventions that each need their own validation.
I think of it like this: a program has a limited amount of real risk it can absorb before a funder or a regulator stops trusting the data. Every new, unproven component adds risk. If you can hold nine variables constant by using known tools, you get a much cleaner read on the one variable you actually care about.
Where This Pays Off Fastest
The clearest payoff shows up in early feasibility work. When you are trying to find out if a cell type will do what you hope inside a living system, you do not want to be troubleshooting a brand-new manufacturing step at the same time. Separate the questions. Answer the biology question with tools you trust. Save your engineering risk for later, once you know the biology is real.
The Shortcut That Does Not Work: Skipping The Boring Validation Step
Here is the one I watch people fall into, especially scientists who are new to running a company instead of a lab. They see a result that looks good enough and they want to move straight to the next milestone. Skip the repeat experiment. Skip the second model. Skip the assay that confirms the mechanism instead of just the outcome.
This feels like speed. It is not. It is borrowing time from a later stage of the program, usually with interest.
I have watched this play out with potency assays in particular. A team gets an early signal that a cell product works, and the instinct is to declare victory and move into scale-up. But if you have not nailed down what is actually driving the effect, you cannot troubleshoot it later when a batch behaves differently. You end up chasing a mystery in a regulatory filing instead of in a notebook, which is a much worse place to be doing basic science.
Why This Mistake Is So Easy To Make
Nobody makes this mistake because they are careless. They make it because the pressure to hit a milestone date is loud, and the cost of skipping validation is quiet. It does not show up for months. By the time it does, it looks like a manufacturing problem or a regulatory problem, not what it actually is: a decision made under time pressure earlier in the program.
My habit now is simple. Before I let a team move past a result, I ask what would have to be true for that result to be wrong. If nobody can answer that quickly, we have not validated enough. This costs a week or two upfront. It has saved months later, more than once.
Telling The Two Apart
The difference between a good shortcut and a bad one comes down to what you are actually skipping.
Reusing a validated platform skips redundant invention. You are not skipping the science. You are choosing not to reinvent tools that already answer known questions reliably.
Skipping validation skips information you will need later. There is no version of a cell therapy program where that information stops being necessary. You are just deciding who has to gather it: you, now, on your schedule, or a regulator, later, on theirs.
I try to teach this distinction to anyone new to a company-building role. Fast and careful are not opposites. Fast and undercharacterized are. The teams that move quickly over the long run are usually the ones who slowed down at the one or two moments that actually mattered, and moved past everything else without hesitation.